Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Biomarkers / PPBP

PPBP

Basics

Aliases:
This biomarker is also known as:
  • TGB1,
  • neutrophil-activating peptide 2,
  • thrombocidin 1,
  • PBP,
  • LA-PF4,
  • platelet basic protein,
  • CTAP-III,
  • B-TG1,
  • THBGB1,
  • NAP-2-L1,
  • TC2,
  • small inducible cytokine B7,
  • small inducible cytokine subfamily B, member 7,
  • connective tissue-activating peptide III,
  • b-TG1,
  • NAP-2,
  • beta-thromboglobulin,
  • CTAPIII,
  • leukocyte-derived growth factor,
  • macrophage-derived growth factor,
  • Beta-TG,
  • thromboglobulin, beta-1,
  • MDGF,
  • CXC chemokine ligand 7,
  • THBGB,
  • LDGF,
  • pro-platelet basic protein (chemokine (C-X-C motif) ligand 7),
  • pro-platelet basic protein,
  • neutrophil-activating peptide-2,
  • thrombocidin 2,
  • low-affinity platelet factor IV,
  • TGB,
  • CTAP3,
  • TC1,
  • CXCL7,
  • SCYB7,

View in BioMuta

Description…

CTAP-III (officially named PPBP) is a platelet-derived growth factor that belongs to the CXC chemokine family. This growth factor is a potent chemoattractant and activator of neutrophils. It has been shown to stimulate various cellular processes including DNA synthesis, mitosis, glycolysis, intracellular cAMP accumulation, prostaglandin E2 secretion, and sythesis of hyaluronic acid and sulfated glycosaminoglycan. It also stimulates the formation and secretion of plasminogen activator by synovial cells.

Attributes

QA State: Curated
Type: Protein
Short Name:
HGNC Name: PPBP

Datasets

There are no datasets associated with this biomarker.

Organs

The following organs have data associated with this biomarker…

Ovary

Attributes

Phase: Three
QA State: Curated

Overview

CTAP-III was identified to be significantly higher in venous than in arterial blood. CTAP III levels decreased after lung tumor resection (P = .01). In two independent population cohorts, CTAP III was significantly associated with lung cancer. CTAP-III may also modify breast cancer cells and surrounding extracellular matrix to facilitate metastasis. In contrast to earlier findings from analyzes of postdiagnostically collected sera, the addition of 7 biomarkers (apolipoprotein A1 (APOA1), truncated transthyretin (TTR), transferrin (TF), hepcidin (HAMP), β-2 microglobulin B2M), connective tissue activating protein III (CTAPIII, a.k.a PPBP) to CA 125 did not improve sensitivity for preclinical diagnosis of ovarian cancer beyond CA 125 alone.

Performance Comment

Of the 28 ovarian cancer biomarkers tested in prediagnostic specimens, from the PLCO, CA125 remains the single best biomarker for ovarian cancer and has its strongest signal within six months of diagnosis. CTAP-III, also known as PPBP, alone was not a strong predictor.

Studies

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

New Funding Opportunity: Biomarker Development Laboratories for the Early Detection Network: Applications Due May 23

Update: Pre-application webinar information now available.

The National Cancer Institute's Division of Cancer Prevention has released a new funding opportunity to solicit organ-specific applications for Biomarker Developmental Laboratories (BDLs), one of the four scientific units of the recently funded Early Detection Research Network (EDRN). The EDRN is a national infrastructure funded to discover, develop, and validate biomarkers for risk assessment, detection, and molecular diagnosis and prognosis of early cancer. BDLs are responsible for the discovery, development, characterization, and testing of new, or the refinement of existing, biomarkers and biomarker assays for risk assessment, detection, and molecular diagnosis and prognosis of cancers.

The existing BDLs are primarily focused on ovary and gastrointestinal cancers. The proposed BDLs (to be supported under this funding opportunity) should be focused on one or more of the following cancers: breast, prostate and other genitourinary organs, or lung. In addition, cancers with rapidly rising incidence rates, e.g., endometrial, hepatocellular, kidney, thyroid, oropharyngeal cancers, and/or cancers with unique etiology, e.g., mesothelioma, will be considered.

The newly funded units of the Early Detection Research Network will be announced later in April. Successful applicants have already been notified. Those researchers who were not successful during the last round of applications are encouraged to apply to this opportunity.